Hoofddorp, the Netherlands, 30 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2020 annual report.
Author: Leunar Miranda Leal
Minutes of the EGM 28 April 2021
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held virtually on 28 April 2021.
IGEA announces extraordinary general meeting results
Hoofddorp, the Netherlands, 28 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that the extraordinary general meeting unanimously approved all the Board of directors’ proposals. The minutes of the meeting is available at https://www.igeapharma.nl/category/information-for-shareholders/
IGEA to secure convertible bond commitment with Negma Group
Hoofddorp, the Netherlands, 15 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the signing of a two-year convertible bond commitment with UAE-based Negma Group.
IGEA and its CFO end collaboration
Hoofddorp, the Netherlands, 14 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that the collaboration with Patrick Pozzorini is terminated. The formed CFO resigned due to personal reasons.
Convening notice
Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the virtual extraordinary general meeting on 28 April 2021 (the “EGM”). The meeting will start at 10:00 hours CEST and is to be attended virtually. Registration will start at 9:30 hours CEST.
IGEA to finalize on convertible bond facility arrangement
Hoofddorp, the Netherlands, 25 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the entry into the final stage of negotiations with an institutional investor, following to a letter of intent (LOI) binding in terms, for a convertible bond facility arrangement over the next 24 months. The closing is expected to be within the first half of April 2021.
Under the terms of the LOI and subject to closing, the investor will commit for up to EUR 10 million over the next 24 months.
IGEA announces three new board members
This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed on https://www.igeapharma.nl/category/press-releases.
Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced important changes in its board of directors. As announced today by separate press release, new persons were bindingly nominated for election as non-executive directors in the board of IGEA at the upcoming extraordinary general meeting of 28 April 2021.
IGEA calls extraordinary general meeting
Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 28 April 2021. The EGM will resolve on matters regarding the business combination with Blue Sky Natural Resources LTD (“BSNR”) as further indicated below (and as previously disclosed by IGEA on 8 August 2020 and 15 February 2021) and on the appointment of newly proposed non-executive directors.
IGEA announces changes in its board
Hoofddorp, the Netherlands, 4 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Camillo Ricordi and Mr. Barth Armand Green from its board of directors for personal reasons.